CO2021008962A2 - Derivados activos de éster de testosterona, composiciones y usos de los mismos - Google Patents

Derivados activos de éster de testosterona, composiciones y usos de los mismos

Info

Publication number
CO2021008962A2
CO2021008962A2 CONC2021/0008962A CO2021008962A CO2021008962A2 CO 2021008962 A2 CO2021008962 A2 CO 2021008962A2 CO 2021008962 A CO2021008962 A CO 2021008962A CO 2021008962 A2 CO2021008962 A2 CO 2021008962A2
Authority
CO
Colombia
Prior art keywords
testosterone
compositions
new
ester derivatives
testosterone ester
Prior art date
Application number
CONC2021/0008962A
Other languages
English (en)
Inventor
Nathan Bryson
Avinash Chander Sharma
Original Assignee
Acerus Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerus Biopharma Inc filed Critical Acerus Biopharma Inc
Publication of CO2021008962A2 publication Critical patent/CO2021008962A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a nuevos compuestos y composiciones que comprenden derivados del ingrediente activo de testosterona y nuevos derivados de testosterona, nuevos métodos de testosterona, nuevas composiciones de testosterona, nuevos artículos de testosterona de fabricación de preparaciones farmacéuticas y nuevos usos terapéuticos de testosterona de los mismos.
CONC2021/0008962A 2018-12-14 2021-07-07 Derivados activos de éster de testosterona, composiciones y usos de los mismos CO2021008962A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862779854P 2018-12-14 2018-12-14
PCT/CA2019/051793 WO2020118437A1 (en) 2018-12-14 2019-12-12 Active ester derivatives of testosterone, compositions and uses thereof

Publications (1)

Publication Number Publication Date
CO2021008962A2 true CO2021008962A2 (es) 2021-10-29

Family

ID=71072219

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0008962A CO2021008962A2 (es) 2018-12-14 2021-07-07 Derivados activos de éster de testosterona, composiciones y usos de los mismos

Country Status (15)

Country Link
US (1) US20200188412A1 (es)
EP (1) EP3893885A4 (es)
JP (1) JP2022517724A (es)
KR (1) KR20210131305A (es)
CN (1) CN113365635A (es)
AU (1) AU2019396139A1 (es)
BR (1) BR112021011525A2 (es)
CA (1) CA3123301A1 (es)
CO (1) CO2021008962A2 (es)
EA (1) EA202191378A1 (es)
IL (1) IL283964A (es)
MX (1) MX2021007032A (es)
SG (1) SG11202106306YA (es)
WO (1) WO2020118437A1 (es)
ZA (1) ZA202104050B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
KR102408399B1 (ko) 2016-03-08 2022-06-13 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
PT1530965E (pt) * 2003-11-11 2006-05-31 Udo Mattern Sistema de administracao de libertacao controlada de hormonas sexuais para aplicacao nasal
EP1729676A1 (en) * 2004-03-15 2006-12-13 Durect Corporation Pharmaceutical compositions for administration to a sinus
CN103705462B (zh) * 2010-04-12 2016-08-31 克劳拉斯医疗有限公司 口服睾酮酯制剂以及包含其的治疗睾酮缺乏症的方法
KR20230041081A (ko) * 2011-05-15 2023-03-23 에이세러스 바이오파마 인크. 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
US20150290217A1 (en) * 2012-11-21 2015-10-15 Trimel Biopharma Srl Male testosterone titration methods, male intranasal testosterone bio-adhesive gel formulations and use thereof for treating hypogonadism and trt
EP4234015A3 (en) * 2013-03-15 2023-11-22 Tolmar, Inc. Methods of treating testosterone deficiency
ES2877107T3 (es) * 2014-08-28 2021-11-16 Univ Texas Formulaciones de testosterona y procedimientos de tratamiento con ellas
EP3265140B1 (en) * 2015-03-02 2021-05-12 Medlab Clinical U.S., Inc. Transmucosal and transdermal delivery systems
CA3016542A1 (en) * 2016-03-02 2017-09-08 Board Of Regents, The University Of Texas System Formulations of testosterone and methods of treatment therewith
WO2017208072A2 (en) * 2016-06-02 2017-12-07 Acerus Pharmaceutical Corporation Nasal cannabidiol compositions

Also Published As

Publication number Publication date
EA202191378A1 (ru) 2021-10-04
SG11202106306YA (en) 2021-07-29
MX2021007032A (es) 2021-10-22
ZA202104050B (en) 2022-04-28
CN113365635A (zh) 2021-09-07
EP3893885A4 (en) 2022-09-07
AU2019396139A1 (en) 2021-07-15
JP2022517724A (ja) 2022-03-10
KR20210131305A (ko) 2021-11-02
CA3123301A1 (en) 2020-06-18
IL283964A (en) 2021-07-29
EP3893885A1 (en) 2021-10-20
US20200188412A1 (en) 2020-06-18
WO2020118437A1 (en) 2020-06-18
BR112021011525A2 (pt) 2021-08-31

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CO2021008962A2 (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
ECSP19078393A (es) Compuestos inhibidores de ask1 y usos de los mismos
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CL2019003309A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019002745A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2020000747A1 (es) Formulaciones de niraparib.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2019002744A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CR20180493A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2019003294A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
ECSP14013275A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
ECSP15000868A (es) Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2018000363A1 (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana.
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
BR112017004948A2 (pt) formulação farmacêutica.
NI202000028A (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2017002229A1 (es) Inhibidores de bace1.